Janssen R&D announced results from a Phase 3 study on the use of initial combination therapy of canagliflozin and metformin extended release (XR) in type 2 diabetes patients with higher A1C levels and who treat their type 2 diabetes with diet and exercise only. The findings were presented at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston, MA.

In the 26-week study, 1,186 patients with type 2 diabetes and inadequate hemoglobin A1c (HbA1C) control despite treatment with diet and exercise were randomized to receive canagliflozin 100mg in combination with metformin XR (median 2,000mg/day), canagliflozin 300mg in combination with metformin XR, canagliflozin 100mg, canagliflozin 300mg, or metformin XR. Comparisons of canagliflozin to metformin were also evaluated.

RELATED: New Combination Tablet OK’d for Type 2 Diabetes

Both groups receiving canagliflozin plus metformin XR had statistically superior HbA1C reductions (-1.77 and -1.78, respectively) vs. patients receiving either canagliflozin 100mg (-1.30), 300mg (-1.37) , or metformin XR (-1.42) alone. Patients taking canagliflozin in combination with metformin XR also had a significant reduction in weight compared to patients treated with metformin XR alone.

For more information visit JanssenRND.com.